ReviewDiagnostics (Basel, Switzerland)2021
The Search for Biomarkers in Fibromyalgia.
Review in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Proteomics in Patients with Fibromyalgia Syndrome: A Systematic Review of Observational Studies.Current pain and headache reports · 2024Pooled it
- Relationship Between Central Sensitization and Genetic Polymorphisms-A Case-Control Study in Fibromyalgia.European journal of pain (London, England) · 2026Trial
- Longitudinal stability of data-driven fibromyalgia phenotypes across repeated clinical assessments.Pain reports · 2026Article
- The Neutrophil-to-Lymphocyte Ratio in Fibromyalgia: A Systematic Review with a Neuroimmune Perspective.Brain sciences · 2026Review
- Point-of-care Diagnostic Framework for Fibromyalgia Using Integrated Vibrational Spectroscopy and Metabolomics.Research square · 2026Article
- Moving Toward Objective Diagnosis in Fibromyalgia: Emerging Biomarkers and Digital Phenotyping Tools.Biomedicines · 2026Review
- Hyperbaric Oxygen Therapy as a Therapeutic Option for Patients with Fibromyalgia.Current rheumatology reviews · 2026Review
- Microglial Activation in Nociplastic Pain: From Preclinical Models to PET Neuroimaging and Implications for Targeted Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Serum GDF15 as a supportive biomarker in female fibromyalgia patients based on a prospective case-control study.Scientific reports · 2025Article
- In Search of Molecular Correlates of Fibromyalgia: The Quest for Objective Diagnosis and Effective Treatments.International journal of molecular sciences · 2025Review
- Article
- Demographic Characteristics and Inflammatory Biomarker Profile in Psoriatic Arthritis Patients with Comorbid Fibromyalgia: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2025Article
- Review
- Biochemical analysis of miR-217 and miR-532 in patients with fibromyalgia.European journal of medical research · 2025Article
- Sensory processing in medically unexplained pain syndrome. A systematic review.Frontiers in pain research (Lausanne, Switzerland) · 2025Review
- Carnitine and Other Metabolites in Fibromyalgia a Clinical Perspective on a Mendelian Randomization Study.Journal of pain research · 2025Article
- Perceived and endocrine acute and chronic stress indicators in fibromyalgia syndrome.Scientific reports · 2024Article
- Fibromyalgia: A Review of the Pathophysiological Mechanisms and Multidisciplinary Treatment Strategies.Biomedicines · 2024Review
- Surface-Enhanced Raman Spectroscopy Combined with Multivariate Analysis for Fingerprinting Clinically Similar Fibromyalgia and Long COVID Syndromes.Biomedicines · 2024Article
- Automated characterization and detection of fibromyalgia using slow wave sleep EEG signals with glucose pattern and D'hondt pooling technique.Cognitive neurodynamics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibromyalgia is the most common of the central sensitivity syndromes affecting 2-5% of the adult population in the United States. This pain amplification syndrome has enormous societal impact as measured by work absenteeism, decreased work productivity, disability and injury compensation and over-utilization of healthcare resources. Multiple studies have shown that early diagnosis of this condition can improve patient outlook and redirect valuable healthcare resources towards more appropriate targeted therapy. Efforts have been made towards improving diagnostic accuracy through updated criteria. The search for biomarkers for diagnosis and verification of Fibromyalgia is an ongoing process. Inadequacies with current diagnostic criteria for this condition have fueled these efforts for identification of a reproducible marker that can verify this disease in a highly sensitive, specific and reproducible manner. This review focuses on areas of research for biomarkers in fibromyalgia and suggests that future efforts might benefit from approaches that utilize arrays of biomarkers to identify this disorder that presents with a diverse clinical phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.